Drug Profile
BAY 1026153
Alternative Names: BAY-1026153Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Endometriosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Endometriosis in Germany
- 31 Dec 2011 Phase-I clinical trials in Endometriosis in Germany (unspecified route)